Treatment of POEMS Syndrome With Daratumumab

Inclusion Criteria: * Patients must have POEMS syndrome and meet the diagnostic criteria for POEMS syndrome as described in Appendix I. * Both newly-diagnosed and relapsed POEMS syndrome will be eligible for inclusion. * Patients must have a platelet count of ≥ 50,000/μL. * Patients must be at least 18 years of age. * Participants must have preserved renal function as defined by a serum creatinine level of \< 3 mg/dL. * Participants must have an ejection fraction by echocardiogram (ECHO) or multigated acquisition (MUGA) scan ≥ 40 percent. * Eastern Cooperative Oncology Group ≥ 1, * Overall Neuropathy Limitations Scale (ONLS) ≥ 1. * Patients must have signed an institutional review board (IRB)-approved informed consent indicating their understanding of the proposed treatment and understanding that the protocol has been approved by the IRB. Exclusion Criteria: * Documented allergy to lenalidomide, DARA, mannitol, other monoclonal antibodies or human proteins and mammalian-derived products. * Prior treatment with DARA or other CD38 monoclonal antibodies * Patients with central nervous system (CNS) Multiple Myeloma (MM) involvement. * Patients who have received an investigational drug or device within 4 weeks prior to enrollment or received live attenuated vaccine within 4 weeks prior to enrollment. * Poorly controlled hypertension, diabetes mellitus, or other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment accor…